Although direct mutations in major HATs (such as EP300 or CREBBP, encoding p300/CBP) are relatively uncommon in AML, oncogenic processes frequently misregulate these enzymes or exploit their functions. This evidence concerns the gene EP300 and acute myeloid leukemia.